Deal Snapshot
AERIE PHARMACEUTICALS TO ACQUIRE SPANISH DRY EYE THERAPIES DEVELOPER AVIZOREX PHARMA
Monday 18 November 2019

US-based ophthalmic pharmaceutical company Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) has signed an agreement for the acquisition of Spanish ophthalmic pharmaceutical company Avizorex Pharma, S.L., the company said.
Avizorex Pharma is developing therapeutics for the treatment of dry eye disease. AVX completed a Phase 2a study in dry eye subjects earlier this year with its lead product candidate, AVX-012.


TKUqg0 http://www.FyLitCl7Pf7kjQdDUOLQOuaxTXbj5iNG.com
Details
Date Published: 18/11/2019
Target: Avizorex Pharma
Country: Spain
Deal Size: 10m (USD)
Sector: Pharmaceuticals
Type: Corporate acquisition
Financing: Cash
Status: Agreed
Vendor:
Buyer: Aerie Pharmaceuticals
Comment:


Options